With Wall Street estimating that non-alcoholic steatohepatitis (NASH) could become up to a $40 billion worldwide market in the next 15 years, it’s no surprise that an indication lacking great name recognition nonetheless is drawing significant interest across the biopharmaceutical industry.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?